Compare Delta Air Lines, Inc. (DAL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Summit Therapeutics Inc — how do they compare? Delta Air Lines, Inc. trades at $89.4 (market cap $59.46B), while Summit Therapeutics Inc trades at $15.21 (market cap $12.06B). The key difference: Delta Air Lines, Inc. is far larger — about 4.9× Summit Therapeutics Inc's market cap, and Delta Air Lines, Inc. pays a 0.86% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DAL | SMMT | |
|---|---|---|
Market Cap | $59.46B | $12.06B |
Sector | Industrials | Health |
52-Week High | $93.66 | $26.98 |
52-Week Low | $55.65 | $12.55 |
Enterprise Value | $74.77B | $11.39B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $89.70, up 0.55% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $1.56 versus $1.49 expected, maintaining a consistent earnings beat streak. Revenue growth has accelerated from $50.6B in 2022 to $63.4B in 2025, while net income improved to $5.0B. Analyst consensus remains overwhelmingly positive with 82% buy ratings and a $108.27 price target representing 21% upside potential.
DAL presents compelling value with attractive valuation multiples (P/E 14.99, P/S 0.87) and strong profitability metrics (ROE 20.12%). Key risks include fuel cost volatility and competitive pressure, but the company's premium travel positioning and American Express partnership provide competitive advantages. The technical setup suggests continued upward momentum with support at $88-90 levels.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
